Michael Retsky (PhD in Physics from University of Chicago) made a career change to cancer research thirty years ago. He was on Judah Folkman’s staff at Harvard Medical School for 12 years. Retsky is Editor with Romano Demicheli of a Springer-Nature book published July 2017 (Perioperative Inflammation as Triggering Origin of Metastasis Development). After diagnosis of stage IIIc colon cancer in 1994, he was the first person to use what is now called metronomic chemotherapy. He is a founder and was on the Board of Directors of the Colon Cancer Alliance.
Retired Physician. Personal: Born 19 December 1947, Amsterdam, The Netherlands. Education: Analytical Chemist, Westeinde Hospital, The Hague, 1967-69; MD, Catholic University, Nijmegen, 1969-80; Course in General and Experimental Oncology, Institute ARC, Villejuif, France, 1985-86; Assessment Medicine, SMI course, School of Public Health, Utrecht, 1999; Course of Counselling and Coaching, Benelux University Centre, Eindhoven, Netherlands, 2002-05. Positions held: Assistant pathologist, clinical and research departments, Amsterdam, Paris, Brussels, 1980-1988; Physician, Bureau of Driving Licenses, Rijswijk, The Netherlands, 1990-1992; Physician of Assurance Medicine, GUO, GAK, ZVN, 1992-99; Physician of Occupational Health, several Arbo Services, 1999-2012. Retired from practice as a physician, 2012
Bimal Krishna Banik obtained his Ph. D. in Chemistry from Jadavpur University based upon his research performed at Indian Association for the Cultivation of Science. He conducted postdoctoral research at Case Western Reserve University and Stevens Institute of Technology. He is a FRSC and CChem of the Royal Society of Chemistry, UK. He is also a Fellow of the Indian Chemical Society. Dr. Banik was a Tenured Full Professor in Chemistry and First President’s Endowed Professor in Science & Engineering at the University of Texas-Pan American (UTPA) and he was also the Vice President of Research & Education Development of the Community Health Systems of South Texas. At present, he is a Full Professor of Prince Mohammad Bin Fahd University, Kingdom of Saudi Arabia.
Dr. Alireza Heidari is a Full Professor and Academic Tenure of Chemistry at California South University (CSU), Irvine, California, USA. He has got his Ph.D. and D.Sc. degrees from California South University (CSU), Irvine, California, USA. Furthermore, he has double postdocs in Project Management, Oncology, Human Cancer Tissues and Synchrotron Radiation from Monash University, Melbourne, Victoria, Australia and also in Nanochemistry and Modern Molecular Electronic–Structure Computations Theory from California South University (CSU), Irvine, California, USA. His research interests include Biophysical Chemistry, Biomolecular Spectroscopy, Quantum Chemistry, Nanochemistry, Modern Electronic Structure Computations, Theoretical Chemistry, Mathematical Chemistry, Computational Chemistry, Vibrational Spectroscopy, Molecular Modelling, Ab initio & Density Functional Methods, Molecular Structure, Biochemistry, Molecular Simulation, Pharmaceutical Chemistry, Medicinal Chemistry, Oncology, Synchrotron Radiation, LASER, Anti–Cancer Nano Drugs, Nano Drugs Delivery, ATR–FTIR Spectroscopy, Raman Spectroscopy, Intelligent Molecules, Molecular Dynamics, Biosensors, Biomarkers, Molecular Diagnostics, Numerical Chemistry, Nucleic Acids, DNA/RNA Monitoring, DNA/RNA Hypermethylation, Human Cancer Tissues, Human Cancer Cells, Tumors, Cancer Tissues, Cancer Cells, etc. He has participated at more than two hundreds reputed international conferences, seminars, congresses, symposiums and forums around the world as yet. Also, he possesses many published articles in Science Citation Index (SCI)/International Scientific Indexing (ISI) Journals. It should be noted that he has visited many universities or scientific and academic research institutes in different countries such as United States, United Kingdom, Canada, Australia, Scotland, Ireland, Netherlands, Belgium, Denmark, Greece, Russia, Estonia, Turkey, France, Swiss, Germany, Sweden, Italy, Austria, Hungary, Poland, Brazil, Spain, Portugal, Mexico, Japan, Singapore, Malaysia, Thailand, Taiwan, South Korea, China, India, Qatar, United Arab Emirates, etc. as research fellow, sabbatical and volunteer researcher or visitor and so on heretofore. He has a history of several years of teaching for college students and various disciplines and trends in different universities. Moreover, he has been a senior advisor in various industry and factories. He is expert in many computer programs and programming languages. Hitherto, he has authored more than twenty books and book chapters in different fields of Chemistry. Syne, he has been awarded more than seven hundreds reputed international awards, prizes, scholarships and honors. Heretofore, he has multiple editorial duties in many reputed international journals, books and publishers. Hitherward, he is a member of more than two hundreds reputed international academic–scientific–research institutes around the world. In addition, he is member of the Nobel committee for Chemistry. It should be noted that he is currently the President of American International Standards Institute (AISI), Irvine, California, USA and also Director of the BioSpectroscopy Core Research Laboratory at California South University (CSU), Irvine, California, USA.
Dr Alrawi is currently the Director of all Surgical Oncology Services at Alzahra Cancer Center in the Heart of Dubai and its tertiary referral cancer center for all UAE, hosting highly specialized surgical oncology subspecialties, including Colorectal, Breast oncology, Head & Neck Surgery, Urology, Gynecological Oncology, Sarcoma/ Melanoma and Peritoneal surface malignancy, in addition to pancreatic and hepatic surgery. DR Alrawi currently was the Chief of Surgical Oncology Divison at Tawam Hospital and was the interim chair of department of surgery from October 2013-September 2015. Tawam Hospital is affiliated with JOHN HOPKINS Medical System. Dr Alrawi major interest is Gastrointestinal Oncology, including Esophageal, Gastric, Pancreas, Liver and colonic surgery with special interest in endocrine surgery including thyroid , parathyroid and adrenal surgery, Sadir Alrawi, was the Chief of the Surgical Oncology Program at Comprehensive Cancer Center of 21st Century in Jacksonville, Florida from 2008- 2013. Prior to that, Dr. Alrawi was an assistant professor in the Department of Surgery/Division of Surgical Oncology at University of Florida, Jacksonville. Dr Alrawi trained in various Academic institutes in Surgical Oncology all over including Roswell Park, Cancer institute, Buffalo, Royal Free Hospital, UC of London and Ninewells Hospital, U of Dundee Dr. Alrawi, who is American board certified, completed his Head & Neck fellowship and Surgical Oncology fellowship at Roswell Park Cancer institute (NCI) designated in 2006. Dr Alrawi did advanced Laparoscpic oncology training with Professor Alfred Cuschieri in Dundee 1992-1993, advanced colorectal oncology training with E Lloyd Davis in Cornwall, England 1993-1995 and advanced surgical oncology with Professor Marc Winslett, London 1995-1996. He has received many academic and scholarly honors while in training and during his clinical practice years, and is an often-invited speaker at both public and professional meetings dedicate to helping education with cancer management. Dr. Alrawi has been involved in numerous research activities throughout his career in an effort to improve our understanding of cancer early diagnosis and multidispilinary approach. In his 28 year experience of Surgical Oncology, Dr Alrawi was able to publish more than 40 papers in per reviewed journals and more than 150 presentations in local, national and international meetings both in clinical and basic siences. Dr. Alrawi is passionate about community outreach, and fervently believes that cancer care and health awareness, coupled with excellence in cancer diagnosis and treatment handled in multidisplinary approach by specialized team, can and will continue to save lives.
Professor Beebe is a Research Professor in the Frank Reidy Research Center for Bioelectrics at Old Dominion University (ODU). He received his PhD in Medical Sciences (Pharmacology) at the University of Toledo College of Medicine in 1982 and was a post-doctoral fellow at the Howard Hughes Medical Institute, Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine. He was a Fulbright and Marshall Scholar in Oslo, Norway. He is the author of 125 peer reviewed manuscripts and books chapters. He was awarded two NIH grants analyzing structure and function of Protein Kinase A and cAMP signal transduction. He now investigates mechanisms of NanoPulse Stimulation (NPS) in cancer and biology. He has trained over 30 graduate students and post-doctoral fellows, is a member of Editorial Boards for four journals and is the Chair of the ODU Institutional Animal Care and Use Committee (IACUC).
NanoPulse Stimulation (NPS) in cancer & Immuno-Oncology Applications
Professor Yoshiaki Omura's far-reaching expertise is rooted in a strong academic background involving an unusual combination of fields including experimental physics, medical electronics, and basic and clinical medicine from both Western and Oriental perspectives. Professor Yoshiaki Omura, MD, ScD, is a cardiologist with a remarkable 50 year career in the medical world. He serves as President of the International College of Acupuncture & Electro-Therapeutics, Adjunct Professor at the Department of Family & Community Medicine of New York Medical College since 2008, Editor-in-Chief of Acupuncture & Electro-Therapeutics Research, International Journal of Integrated Medicine since 1974, and Director of Medical Research of Heart Disease Research Foundation from 1972 to 2016. He received his B.Sc in Applied Physics at Waseda University Tokyo & M.D. at the Yokohama City University in Japan and trained first at Tokyo University & graduated from Columbia University where he received Cardiovascular Fellowship & Resident Training in Oncological Surgery & his degree of Sc.D. in Pharmaco-Electrophysiology of Single Cardiac Cells in Vivo & in Vitro. Professor Yoshiaki Omura is a specialist in cardiology, oncology, acupuncture & electro-therapeutics and basic & clinical research in these fields. He is a Life Fellow of the Royal Society of Medicine (England), the American College of Acupuncture, and the American Association of Integrative Medicine, as well as Fellow of the International College of Acupuncture and Electro-therapeutics. He published over 270 original research reports and 9 books. Formerly Maitre de Recherche at INSERM (National Institute of Health & Medical Research) of French Government; formerly visiting Prof. of Psychophysiology at University of Paris (No. 4) & visiting Prof. & Research Consultant of Electro-anesthesia & Neuroelectricity at University of Rene Descartes of University of Paris (No. 5); visiting Research Prof. of Electrical Engineering Dept. at Manhattan College; formerly Adjunct Prof. of Pharmacology at Chicago Medical School; visiting Prof. of Anesthesiology Dept. at University of Padua, Italy; formerly Adjunct Prof. of Physiology at Showa University Medical School, Tokyo; formerly Prof. of Non-orthodox Medicine at Ukrainian Kiev National Medical University, and visiting Prof. at Ningxia University Medical School, China. Professor Omura teaches or gives consultations through the activity of his associated organizations and by request of other doctors and medical organizations. He is Life Fellow of: The Royal society of Medicine (England), American College of Acupuncture, American Association of Integrative Medicine, Fellow and President of the International College of Acupuncture and Electrotherapeutics. Professor Omura has done extensive research on the effects of chemotherapy on the heart and brain of cancer patients since he noticed many cancer patients developed memory problems and complain of heaviness in chest or mild chest pain after chemotherapy. While most ECGs do not show any significant changes by chemotherapy, he found significant biochemical changes in specific part of the rising part of the T-waves without significant visible changes in ECGs. He also developed a method to identify any infection of any part of the heart from ECG, and he is the first one to report in late 1990s that repeated Acupuncture treatment of Lyme Disease infected joint pain is one of the significant unrecognized causes of atrial flutters and atrial fibrillations by spreading of Lyme disease's Spirocheta by rupturing capillaries of Borrelia Burgdorferi infected painful joints. Recently he succeeded in developing a new method of screening cancers from
DR. ALAIN L. FYMAT, PhD, he is a medical-physical scientist and an educator. He is the current President/CEO and Professor at the International Institute of Medicine & Science with a previous appointment as Executive Vice President/Chief Operating Officer and Professor at the Weil Institute of Critical Care Medicine, California, U.S.A. He was formerly Professor of Radiology, Radiological Sciences, Radiation Oncology, Critical Care Medicine and Physics at several U.S. and European Universities. Earlier, he was Deputy Director (Western Region) of the U.S. Department of Veterans Affairs (Office of Research Oversight). At the Loma Linda Veterans Affairs Medical Center, he was Scientific Director of Radiology, Director of the Magnetic Resonance Imaging Center and, for a time, Acting Chair of Radiology. Previously, he was also Director of the Division of Biomedical and Biobehavioral Research at the University of California at Los Angeles/Drew University of Medicine and Science. He is also Health Advisor to the American Heart & Stroke Association, Coachella Valley Division, California. He is a frequent Keynote Speaker and International Organizing Committee Member of several international scientific conferences. He has lectured extensively in the U.S., Europe, Asia and Africa. He has published ~ 425 scholarly scientific publications and books. He is also Editor-in-Chief, Honorable Editor or Editor of 62 medical/scientific Journals. Dr. Fymat is a Board member of several institutions, a member of the New York Academy of Sciences and a reviewer for the prestigious UNESCO Newton Prize, United Kingdom National Commission for UNESCO. His current research interests are focused on nanomedicine, precision/personalized medicine, neurodegenerative diseases (including Alzheimer, Parkinson, epilepsy, dementias) with many open literature contributions in these several areas.
Interface between science and medicine, particularly nanomedicine, nanobiotechnology, cancer/oncology, molecular/personal/precision medicine, human genetics/ epigenetics/ ecogenetics, neurodegenerative diseases, and pharmacogenomics, nanotechnology and cancer, nanochemotherapy, nanoneurology, natural and synthetic immunotherapy, drug delivery across the brain protective barriers, and neurodegenerative disorders (epilepsy, Parkinson's and Alzheimer's diseases).
Andrey Sorokin graduated from the St. Petersburg State University and received his Ph.D. from the Institute of Cytology Academy of Sciences of Russia in 1981. A. Sorokin is a Head of the Laboratory at the Medical College of Wisconsin, where he is holding the position of Full Professor of Medicine with secondary appointments at Department of Physiology and Department of Microbiology & Immunology. He has published more than 100 papers in reputed journals and is serving as an editorial board member of a number of journals including Frontiers in Renal and Epithelial Physiology.
Ziding F completed his PhD from Cornell University. He is a professor, Kathryn O’Connor Research Professor, and Section Chief of Early Detection and Biomarkers in the Department of Biostatistics, and Co-Director of the Center for Global Cancer Early Detection at UT MD Anderson Cancer Center. He has been the Principal Investigator of the Data Management and Coordinating Center (DMCC) for the Early Detection Research Network (EDRN) since 2000, and of the Coordinating and Data Management Center for the Consortium to Study Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC) since 2015. He also has a grant from NCI to incorporate biomarkers to improve lung cancer risk prediction model using PLCO specimens and data. He is the coordinating center PI for a study funded by Cancer Prevention Research Institute of Texas (CPRIT) to establish a large cohort of cirrhosis patients to improve early detection of HCC.